NASDAQ · ZYME
Zymeworks Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ZYME: Nov 5, 2026
Zymeworks Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $2.4. The reported EPS for the same quarter last year was $-0.26.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.40 | $2.69 | $2.14 | 4 |
| Dec 2026 | $-0.02 | $0.67 | $-0.48 | 4 |
| Mar 2027 | $0.45 | $1.05 | $-0.15 | 2 |
| Jun 2027 | $-0.14 | $-0.11 | $-0.16 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews- Zacks · Oct 29, 9:00 AM EDTZymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthZymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- MarketBeat · Oct 27, 7:04 PM EDTZymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal UpsideZymeworks Offers Hope for More than Just Long-Term InvestorsZymeworks (NASDAQ:ZYME) outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced co
- RTTNews · Oct 23, 9:01 AM EDTZymeworks Licenses Cancer Drug Candidate ZW209 To Roche In Deal Worth Up To $813 Million(RTTNews) – Zymeworks (ZYME) has entered into an exclusive global license and collaboration agreement with Roche (RHHBY) for ZW209, a trispecific T-cell engager being developed for cancers that express DLL3, a protein commonly found in small cell lung cancer and certain neuroendo
- MarketBeat · Oct 2, 7:02 PM EDTZymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 OutlookZymeworks Offers Hope for More than Just Long-Term InvestorsZymeworks (NASDAQ:ZYME) said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a com
- RTTNews · Sep 28, 6:36 AM EDTZymeworks Issues Updated 2026 Financial Guidance(RTTNews) – Zymeworks (ZYME) said the company now expects total revenue for 2026 to be between $278 million and $292 million and 2026 adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions. The company announced the updated fi
- RTTNews · Sep 11, 11:45 AM EDTNew FDA Drug Approvals – August 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.
- Zacks · Sep 1, 12:02 PM EDTJAZZ Rises on Updated OS Results From Gastric Cancer StudyJazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
- Zacks · Aug 26, 12:29 PM EDTJAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric CancerJazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
- RTTNews · Aug 25, 12:49 PM EDTZymeworks Gains $250 Mln Payday On FDA Approval For Ziihera In GEA Cancers; Stock Down(RTTNews) – Zymeworks Inc. (ZYME), a biotechnology company, announced on Tuesday receipt of approval from the U.S. Food and Drug Administration (FDA) for Ziihera in two combination regimens for treating HER2+ gastroesophageal adenocarcinoma. The drug is currently licensed to Jazz
- Zacks · Aug 11, 9:30 AM EDTTBPH Meets Q2 Earnings Estimates, to be Acquired by ZymeworksTheravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
- Zacks · Aug 6, 7:10 PM EDTZymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue EstimatesZymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jun 30, 8:54 AM EDTTheravance Stock Down 3% After Zymeworks Announces BuyoutTBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Zymeworks Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.